Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer

NCT00642018 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00642018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00642018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
April 30, 2012
Enrollment
154 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer